Q2-osavuosiraportti
50 päivää sitten‧52 min
Tarjoustasot
Oslo Børs
Määrä
Osto
527
Myynti
Määrä
96
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 336 | - | - | ||
| 97 | - | - | ||
| 1 500 | - | - | ||
| 17 | - | - | ||
| 2 | - | - |
Ylin
60,4VWAP
Alin
59,2VaihtoMäärä
1,2 19 832
VWAP
Ylin
60,4Alin
59,2VaihtoMäärä
1,2 19 832
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 5.5. | |
| 2024 Q4-osavuosiraportti | 19.2. | |
| 2024 Q3-osavuosiraportti | 13.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
11.9.·investtech Out with a long-term analysis on PHO; The stock gave a buy signal from a rectangle formation upon breaking up through resistance at 60.17. Further rise to 78.06 or more is signaled. Resistance 64.
1 päivä sitten·We disagree and wait 29 days from today and see what happens and then what the CEO says when 3Q is presented.
23 t sitten·Ok to inform you a little then. It is not that the review does not start until you are in the number 1 place in the queue. The review is ongoing all the time and the company that submits the application is in direct contact with its case manager. Cevira is now in phase two of the review after they submitted supplementary information that they were asked for by the authorities after they went through phase 1 of the review. The authorities have a deadline of 60 working days to come up with a final answer (start date 4 August), but such an application is moving in the queue now so it will go faster than the 60 days. There it is explained why I said about 30 days before you have the answer. Out of the queue = finished review.
1.9.·Aseris up 8% today. We are getting closer to an approval that will be a game changer for photocure.- 28.8.28.8.APL-1702, a breakthrough therapy for precancerous cervical lesions, is in the final stages before its China launch.
28.8.·Asieris's half-yearly report conveys that the regulatory process (which is in its final stages) for Cevira is going "smoothly" and that market access is "close/imminent".28.8.28.8.APL-1702, a breakthrough therapy for precancerous cervical lesions, is in the final stages before its China launch.- 8.8.8.8.:stethoscope: Exciting progress in the fight against high-grade squamous intraepithelial lesions (HSIL)! Asieris Pharmaceuticals has announced that its innovative photodynamic therapy candidate, Cevira (APL-1702), has advanced to the second round of technical review for its New Drug Application. This milestone brings us closer to a non-surgical treatment option for HSIL, addressing a critical need in patient care. Through proactive engagement with the Center for Drug Evaluation, Asieris aims to expedite the regulatory process, ensuring rigorous evaluation and faster potential access. Developed in collaboration with Photocure, Cevira uses a targeted photosensitizer activated by light, demonstrating efficacy and safety by achieving its primary endpoint in Phase III clinical trials. This advancement highlights the transformative potential of photodynamic therapies in offering minimally invasive, effective treatments for pre-cancerous conditions. The partnership between Asieris Pharmaceuticals and Photocure exemplifies how strategic collaboration in the pharmaceutical industry can accelerate innovation and improve patient outcomes. As Cevira moves forward, it sets a promising precedent for future developments in photodynamic therapy, expanding treatment options and elevating standards of care. https://www.linkedin.com/posts/market-access-today_asieris-moves-cevira-forward-in-nda-technical-activity-7359276352199426049-ntwE?utm_source=share&utm_medium=member_ios&rcm=ACoAAAAsg_4Bjmz1XWELi1GSZ0Od8Vr_XBaxAR4
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
50 päivää sitten‧52 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.9.·investtech Out with a long-term analysis on PHO; The stock gave a buy signal from a rectangle formation upon breaking up through resistance at 60.17. Further rise to 78.06 or more is signaled. Resistance 64.1 päivä sitten·We disagree and wait 29 days from today and see what happens and then what the CEO says when 3Q is presented.23 t sitten·Ok to inform you a little then. It is not that the review does not start until you are in the number 1 place in the queue. The review is ongoing all the time and the company that submits the application is in direct contact with its case manager. Cevira is now in phase two of the review after they submitted supplementary information that they were asked for by the authorities after they went through phase 1 of the review. The authorities have a deadline of 60 working days to come up with a final answer (start date 4 August), but such an application is moving in the queue now so it will go faster than the 60 days. There it is explained why I said about 30 days before you have the answer. Out of the queue = finished review.
- 1.9.·Aseris up 8% today. We are getting closer to an approval that will be a game changer for photocure.
- 28.8.28.8.APL-1702, a breakthrough therapy for precancerous cervical lesions, is in the final stages before its China launch.
- 28.8.·Asieris's half-yearly report conveys that the regulatory process (which is in its final stages) for Cevira is going "smoothly" and that market access is "close/imminent".28.8.28.8.APL-1702, a breakthrough therapy for precancerous cervical lesions, is in the final stages before its China launch.
- 8.8.8.8.:stethoscope: Exciting progress in the fight against high-grade squamous intraepithelial lesions (HSIL)! Asieris Pharmaceuticals has announced that its innovative photodynamic therapy candidate, Cevira (APL-1702), has advanced to the second round of technical review for its New Drug Application. This milestone brings us closer to a non-surgical treatment option for HSIL, addressing a critical need in patient care. Through proactive engagement with the Center for Drug Evaluation, Asieris aims to expedite the regulatory process, ensuring rigorous evaluation and faster potential access. Developed in collaboration with Photocure, Cevira uses a targeted photosensitizer activated by light, demonstrating efficacy and safety by achieving its primary endpoint in Phase III clinical trials. This advancement highlights the transformative potential of photodynamic therapies in offering minimally invasive, effective treatments for pre-cancerous conditions. The partnership between Asieris Pharmaceuticals and Photocure exemplifies how strategic collaboration in the pharmaceutical industry can accelerate innovation and improve patient outcomes. As Cevira moves forward, it sets a promising precedent for future developments in photodynamic therapy, expanding treatment options and elevating standards of care. https://www.linkedin.com/posts/market-access-today_asieris-moves-cevira-forward-in-nda-technical-activity-7359276352199426049-ntwE?utm_source=share&utm_medium=member_ios&rcm=ACoAAAAsg_4Bjmz1XWELi1GSZ0Od8Vr_XBaxAR4
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
527
Myynti
Määrä
96
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 336 | - | - | ||
| 97 | - | - | ||
| 1 500 | - | - | ||
| 17 | - | - | ||
| 2 | - | - |
Ylin
60,4VWAP
Alin
59,2VaihtoMäärä
1,2 19 832
VWAP
Ylin
60,4Alin
59,2VaihtoMäärä
1,2 19 832
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 5.5. | |
| 2024 Q4-osavuosiraportti | 19.2. | |
| 2024 Q3-osavuosiraportti | 13.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
50 päivää sitten‧52 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 5.5. | |
| 2024 Q4-osavuosiraportti | 19.2. | |
| 2024 Q3-osavuosiraportti | 13.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.9.·investtech Out with a long-term analysis on PHO; The stock gave a buy signal from a rectangle formation upon breaking up through resistance at 60.17. Further rise to 78.06 or more is signaled. Resistance 64.1 päivä sitten·We disagree and wait 29 days from today and see what happens and then what the CEO says when 3Q is presented.23 t sitten·Ok to inform you a little then. It is not that the review does not start until you are in the number 1 place in the queue. The review is ongoing all the time and the company that submits the application is in direct contact with its case manager. Cevira is now in phase two of the review after they submitted supplementary information that they were asked for by the authorities after they went through phase 1 of the review. The authorities have a deadline of 60 working days to come up with a final answer (start date 4 August), but such an application is moving in the queue now so it will go faster than the 60 days. There it is explained why I said about 30 days before you have the answer. Out of the queue = finished review.
- 1.9.·Aseris up 8% today. We are getting closer to an approval that will be a game changer for photocure.
- 28.8.28.8.APL-1702, a breakthrough therapy for precancerous cervical lesions, is in the final stages before its China launch.
- 28.8.·Asieris's half-yearly report conveys that the regulatory process (which is in its final stages) for Cevira is going "smoothly" and that market access is "close/imminent".28.8.28.8.APL-1702, a breakthrough therapy for precancerous cervical lesions, is in the final stages before its China launch.
- 8.8.8.8.:stethoscope: Exciting progress in the fight against high-grade squamous intraepithelial lesions (HSIL)! Asieris Pharmaceuticals has announced that its innovative photodynamic therapy candidate, Cevira (APL-1702), has advanced to the second round of technical review for its New Drug Application. This milestone brings us closer to a non-surgical treatment option for HSIL, addressing a critical need in patient care. Through proactive engagement with the Center for Drug Evaluation, Asieris aims to expedite the regulatory process, ensuring rigorous evaluation and faster potential access. Developed in collaboration with Photocure, Cevira uses a targeted photosensitizer activated by light, demonstrating efficacy and safety by achieving its primary endpoint in Phase III clinical trials. This advancement highlights the transformative potential of photodynamic therapies in offering minimally invasive, effective treatments for pre-cancerous conditions. The partnership between Asieris Pharmaceuticals and Photocure exemplifies how strategic collaboration in the pharmaceutical industry can accelerate innovation and improve patient outcomes. As Cevira moves forward, it sets a promising precedent for future developments in photodynamic therapy, expanding treatment options and elevating standards of care. https://www.linkedin.com/posts/market-access-today_asieris-moves-cevira-forward-in-nda-technical-activity-7359276352199426049-ntwE?utm_source=share&utm_medium=member_ios&rcm=ACoAAAAsg_4Bjmz1XWELi1GSZ0Od8Vr_XBaxAR4
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
527
Myynti
Määrä
96
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 336 | - | - | ||
| 97 | - | - | ||
| 1 500 | - | - | ||
| 17 | - | - | ||
| 2 | - | - |
Ylin
60,4VWAP
Alin
59,2VaihtoMäärä
1,2 19 832
VWAP
Ylin
60,4Alin
59,2VaihtoMäärä
1,2 19 832
Välittäjätilasto
Dataa ei löytynyt